Vaccination against Her-2/neu, with focus on peptide-based vaccines.

Tobias, J; Garner-Spitzer, E; Drinic, M; Wiedermann, U

Tobias, J; Garner-Spitzer, E; Drinic, M; Wiedermann, U.

Afiliação

Tobias J; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria. Electronic address: joshua.tobias@meduniwien.ac.at.
Garner-Spitzer E; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Drinic M; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Wiedermann U; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria. Electronic address: ursula.wiedermann@meduniwien.ac.at.

ESMO Open ; 7(1): 100361, 2022 02.

Article em En | MEDLINE | ID: mdl-35026721

Assuntos

Vacinas Anticâncer; Vacinas Anticâncer/uso terapêutico; Humanos; Recidiva Local de Neoplasia/tratamento farmacológico; Peptídeos; Vacinação; Vacinas de Subunidades Antigênicas/farmacologia; Vacinas de Subunidades Antigênicas/uso terapêutico

Palavras-chave

B-cell peptide vaccine/mimotopes; Her-2/neu; T-cell peptide vaccine; cancer; vaccination

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 Base de dados: MEDLINE Assunto principal: Vacinas Anticâncer Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google